On the other hand, preclinical studies have demonstrated that TIGIT blockade enhances anti-tumor T cell responses, reduces tumor growth, and restores CD8+ T cell potency, particularly when combined with PD-1 or PD-L1 inhibitors [296–298]. This evidence concerns the gene CD8A and neoplasm.